疏风解毒胶囊治疗慢性阻塞性肺疾病急性加重期痰热壅肺证疗效观察

Observation of the clinical efficacy of Shufeng Jiedu Capsule in the treatment of acute exacerbation of chronic obstructive pulmonary disease with syndrome of phlegm-heat obstructing the lung

目的探讨疏风解毒胶囊治疗慢性阻塞性肺疾病急性加重期(AECOPD)痰热壅肺证的临床疗效。方法选取AECOPD痰热壅肺证患者120例,按就诊顺序分为试验组和对照组各60例,对照组采用常规治疗,试验组在对照组基础上加用疏风解毒胶囊治疗。入院时和入院后24、72 h检测血清淀粉样蛋白A(SAA)、高敏C反应蛋白(Hs-CRP)、白介素1β(IL-1β)、白介素6(IL-6)含量,并观察临床疗效。结果 2组血气、肺功能、体温入院时与入院后72 h组内比较及入院后72 h组间比较,差异均无统计学意义(P>0.05);入院后72 h咳嗽症状分级2组差异有统计学意义(P<0.05)。入院时2组SAA、Hs-CRP、IL-1β、IL-6含量差异无统计学意义(P>0.05);入院后24 h,试验组SAA、Hs-CRP、IL-6含量均较对照组显著降低,差异有统计学意义(P<0.05),IL-1β2组间差异无统计学意义(P>0.05);入院后72 h,试验组SAA、Hs-CRP、IL-1β、IL-6含量均较对照组显著降低,差异有统计学意义(P<0.05)。结论在常规治疗基础上加用疏风解毒胶囊治疗AECOPD临床有效。

Objective To investigate the clinical efficacy of Shufeng Jiedu Capsule in the treatment of acute exacerbation of chronic obstructive pulmonary disease （AECOPD） with syndrome of phlegm-heat obstructing the lung. Methods According to the visit order, 120 cases of AECOPD patients with syndrome of phlegm-heat obstructing the lung were selected and divided into a test group of 60 cases （routine treatment and Shufeng Jiedu Capsule） and a control group of 60 cases （routine treatment） . The contents of serum amyloid A （SAA）, high sensitive C reactive protein （Hs-CRP） and interleukin 1 β （IL-1β）, interleukin 6 （IL-6） and the clinical efficacy were observed before admission and after admission in 24 h and 72 h. Results To compare the blood gas, pulmonary function and body temperature before admission and after admission in 72 h within the groups and after admission in 72h between the two groups, the difference had no statistical significance （P 〉 0. 05 ） ; after admission in 72 h, the differences in cough grading had statistical significance between the two groups （P 〈 0. 05 ） . At admission, the difference of contents of SAA, Hs-CRP, IL-1β and IL- 6 had no statistical significance between the two groups （P 〉 0. 05 ） ; after admission in 24 h, SAA, Hs-CRP, IL-6 in the test group were reduced obviously compared with the control group, the difference had statistical significance （P 〈 0. 05）, but no significance in IL-1β between the two groups （P 〉 0. 05 ） . After the admission in 72 h, the contents of SAA, Hs-CRP, IL-1 β, and IL-6 in the test group were obviously reduced compared with the control group, the difference had statistical significance （P 〈 0. 05）. Conclusion It is clinically effective to combine Shufeng Jiedu Capsule with routine treatment for AECOPD.